Following a full submission
Atomoxetine (Strattera) is not recommended for use within NHS Scotland for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older or in adolescents. This advice concerns use in children and adolescents only and does not cover use in adults.
Atomoxetine is no more effective than a stimulant preparation against which it has been assessed. Tolerability was similar, though with some differences in the individual adverse events reported. Unlike the available stimulant preparations, it is not a Controlled Drug under the Misuse of Drugs regulations 2001 and there is evidence that it lacks abuse potential.
However, the economic case has not been demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- Atomoxetine (Strattera®)
- SMC ID:
- 153/05
- Indication:
- Attention-Deficit/Hyperactivity Disorder
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 March 2005